PsyBio Therapeutics to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th
OXFORD, Ohio and COCONUT CREEK, Fla., Oct. 11, 2021 /PRNewswire/ -- PsyBio Therapeutics Corp. (TSXV: PSYB, OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company developing novel, bespoke, approvable, psycho-targeted therapeutics to improve mental and neurological health, today announced that Evan Levine, CEO and Chairman of PsyBio, will present at the KCSA Psychedelics Investor Conference to be held at VirtualInvestorConferences.com on Thursday, October 14th at 10:30 a.m. ET.
To attend the conference, please register here.
For more information on the conference, or to schedule a one-on-one meeting with the PsyBio management team, please contact KCSA Strategic Communications at PsyBio@kcsa.com.
About PsyBio Therapeutics Corp.
View original content to download multimedia:https://www.prnewswire.com/news-releases/psybio-therapeutics-to-present-at-the-kcsa-psychedelics-virtual-investor-conference-on-october-14th-301396206.html
Company Codes: OTC-PINK:PSYBF, TorontoVE:PSYB, OTC-QB:PSYBF
© 2021 PR Newswire. All Rights Reserved.